MAPK1 and asthma: Currently there is no specific therapy for ozone related asthma complications and our data suggest both p38 and JNK are potential targets for additional therapeutic candidates; and that inhibitors could be tested as prophylactic treatment for asthma exacerbations on days with anticipated high ozone.